Table 1.
Characteristics of the BRAF-mutated PTC patient cohort.
| Characteristic | BRAF-mutated | BRAF wild-type | P value |
|---|---|---|---|
| Total | 237 | 257 | |
| Sex | 0.656 | ||
| Female | 171 (72.15%) | 190 (73.93%) | |
| Male | 66 (27.85%) | 67 (26.07%) | |
| Age | 0.049 | ||
| ≤40 | 154 (64.98%) | 188 (73.15%) | |
| >40 | 83 (35.02%) | 69 (26.85%) | |
| Radiotherapy | 0.123 | ||
| Yes | 133 (56.12%) | 156 (60.70%) | |
| No | 95 (40.08%) | 83 (32.30%) | |
| Unknown | 9 (3.80%) | 18 (7.00%) | |
| Metastasis stage | 0.119 | ||
| M0 | 141 (59.49%) | 135 (52.53%) | |
| M1+MX | 96 (40.51%) | 122 (47.47%) | |
| Lymph node stage | 0.151 | ||
| N0 | 100 (42.19%) | 125 (48.64%) | |
| N1+NX | 137 (57.81%) | 132 (51.36%) | |
| Tumor stage | 0.014 | ||
| T1+T2 | 133 (56.12%) | 172 (66.93%) | |
| T3+T4+TX | 104 (43.88%) | 85 (33.07%) | |
| Neoplasm disease stage | 0.045 | ||
| Stage1+stage2 | 147 (62.45%) | 182 (70.82%) | |
| Stage3+stage4 | 89 (37.55%) | 75 (29.18%) |
Bold values indicate statistically significant (P<0.05).